Page last updated: 2024-10-26

dipyridamole and Amebiasis

dipyridamole has been researched along with Amebiasis in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Amebiasis: Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Evdokiou, A1
Marciano-Cabral, F1
Jamerson, M1

Other Studies

1 other study available for dipyridamole and Amebiasis

ArticleYear
Studies on the cyst stage of Naegleria fowleri in vivo and in vitro.
    The Journal of eukaryotic microbiology, 2022, Volume: 69, Issue:2

    Topics: Amebiasis; Animals; Central Nervous System Protozoal Infections; Cysts; Dipyridamole; Disease Models

2022